We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 (TACOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04306705
Recruitment Status : Unknown
Verified March 2020 by YIKAI YU, Tongji Hospital.
Recruitment status was:  Recruiting
First Posted : March 13, 2020
Last Update Posted : March 17, 2020
Hubei Xinhua Hospital
Wuhan No.1 Hospital
Wuhan Central Hospital
Information provided by (Responsible Party):
YIKAI YU, Tongji Hospital

Tracking Information
First Submitted Date March 8, 2020
First Posted Date March 13, 2020
Last Update Posted Date March 17, 2020
Actual Study Start Date February 20, 2020
Estimated Primary Completion Date May 30, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: March 12, 2020)
Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14 [ Time Frame: First dose date up to 14 days ]
This is a composite outcome measure. Criteria for fever normalization: Temperature < 36.6 °C armpit, < 37.2 °C oral sustained for at least 72 hours and criteria for oxygen normalization: peripheral capillary oxygen saturation (Sp02) > 94% sustained for at least 72 hours.
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: March 12, 2020)
  • Duration of hospitalization [ Time Frame: Up to 28 days ]
    Measured in days
  • Proportion of Participants With Normalization of Fever Through Day 14 [ Time Frame: First dose date up to 14 days ]
    Criteria for: Temperature < 36.6 °C armpit, < 37.2 °C oral, or < 37.8 °C rectal sustained for at least 72 hours.
  • Change from baseline in white blood cell and differential count [ Time Frame: Day 1 through Day 28 ]
    Blood routine test
  • Time to first negative in 2019 novel Corona virus RT-PCR test [ Time Frame: Up to 28 days ]
    Oropharyngeal or anal swabs
  • All-cause mortality [ Time Frame: up to 12 weeks ]
    Date and cause of death (if applicable).
  • Change from baseline in hsCRP [ Time Frame: Day 1 through Day 28 ]
    Serum hsCRP
  • Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α [ Time Frame: Day 1 through Day 28 ]
    Serum inflammatory cytokines
  • Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells [ Time Frame: Day 1 through Day 28 (if applicable) ]
    Flow cytometry for peripheral whole blood
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19
Official Title A Retrospective Study of Evaluating Safety and Efficacy of Tocilizumab Compared to Continuous Renal Replacement Therapy in Controlling CRS Triggered by COVID-19
Brief Summary Some patients infected with the COVID-19 can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. Tocilizumab was first approved by the U.S. FDA in 2010 for rheumatoid arthritis and might now be used to treat serious COVID-19 patients with lung damage, according to China's National Health Commission updated its treatment guidelines in 7th version.Continuous Renal Replacement Therapy (CRRT) was recommended by China's National Health Commission treatment guidelines in 1st-7th version to control sever COVID-19 patients.
Detailed Description Tocilizumab doesn't directly kill the novel coronavirus. It's known as an inhibitor of the receptor of interleukin 6 (IL-6), a pro-inflammatory cytokine. In the disease COVID-19, the body may respond to the pathogen by overproducing immune cells and their signaling molecules in a dangerous phenomenon called cytokine release storm.It has been recently speculated that IL-6 as a main culprit in that immune over activation among COVID-19 patients, hence the Tocilizumab clinical trial was initiated. In 2017, the FDA also approved Tocilizumab to treat cytokine release syndrome (CRS), a form of cytokine storm caused by CAR-T treatment. The investigator's hypothesis was that Tocilizumab would be associated with better clinical outcomes, such as decreased systemic inflammation, improved survival rate, better hemodynamic and improved of respiratory distress.Systemic inflammatory response syndrome was one of the main indications for treatment with CRRT. So it is clinically significant to compare the efficacy and safety of Tocilizumab and CRRT in management of CRS triggered by COVID-19.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Laboratory (RT-PCR) confirmed infection with 2019-nCoV. Lung involvement confirmed with chest imaging Hospitalized with a SaO2/SPO2≤93% on room air or Pa02/Fi02 ratio <300mmHg and ≤14 days since illness onset.
  • Covid-19
  • SARS
  • Cytokine Storm
  • Cytokine Release Syndrome
  • Tocilizumab
  • Drug: Tocilizumab
    Administered as an intravenous infusion.
    Other Name: Actemra
  • Other: Standard of care
    Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.
  • Procedure: Continuous renal replacement therapy
    Catheter insertion site is femoral vein.
Study Groups/Cohorts
  • Tocilizumab
    Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no less than 60 minutes. Tocilizumab was administered according to the local label.
    • Drug: Tocilizumab
    • Other: Standard of care
  • Continuous Renal Replacement Therapy
    Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive 3 times or more.
    • Other: Standard of care
    • Procedure: Continuous renal replacement therapy
  • Standard care
    Standard of care therapy per local written policies or guidelines.
    Intervention: Other: Standard of care
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: March 12, 2020)
Original Estimated Enrollment Same as current
Estimated Study Completion Date June 20, 2020
Estimated Primary Completion Date May 30, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Agrees to the collection of oropharyngeal or anal swabs and venous blood per protocol.
  2. Male or non-pregnant female adult ≥18 years of age at time of enrollment.
  3. Has laboratory-confirmed novel coronavirus infection as determined by polymerase chain reaction (PCR), or other commercial or public health assay in oropharyngeal or anal specimen within 72 hours prior to hospitalization.
  4. Illness of any duration, and at least one of the following:

    1. Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR
    2. Clinical assessment (evidence of rales/crackles on physical examination) AND SpO2 ≤93% on room air, OR
    3. Requiring mechanical ventilation and/or supplemental oxygen, OR
    4. Sustained fever in the past 24 hours and unresponsive to NSAID or steroid
  5. Serum IL-6 ≥3 times the upper limit of normal

Exclusion Criteria:

  1. Alanine transaminase/aspartate transaminase (ALT/AST) > 5 times the upper limit of normal.
  2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated glomerular filtration rate (eGFR) < 30 ml /min/1.73 m^2)
  3. Hemoglobin<80 g/L
  4. Leukocytes<2.0×10^9
  5. Platelets<50×10^9
  6. Pregnancy or breast feeding.
  7. Anticipated transfer to another hospital which is not a study site within 72 hours.
  8. Expected life span does not exceed 7 days.
  9. Allergy to any study medication.
Sexes Eligible for Study: All
Ages 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries China
Removed Location Countries  
Administrative Information
NCT Number NCT04306705
Other Study ID Numbers WHTJCOVID-19
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
IPD Sharing Statement Not Provided
Current Responsible Party YIKAI YU, Tongji Hospital
Original Responsible Party Same as current
Current Study Sponsor Tongji Hospital
Original Study Sponsor Same as current
  • Hubei Xinhua Hospital
  • Wuhan No.1 Hospital
  • Wuhan Central Hospital
Study Director: SHAOXIAN HU, M.D Tongji Hospital
PRS Account Tongji Hospital
Verification Date March 2020